Literature DB >> 30636004

Use of bone age for evaluating bone density in patients with Duchenne muscular dystrophy: A preliminary report.

Asma Al-Zougbi1, Katherine D Mathews2,3, Amal Shibli-Rahhal1.   

Abstract

INTRODUCTION: Patients with Duchenne muscular dystrophy (DMD) exhibit low bone mineral density and increased fracture risk. Because glucocorticoid therapy results in delayed puberty and short stature, it is important to account for delayed skeletal development when interpreting patients' bone mineral density.
METHODS: Twelve glucocorticoid-treated patients with DMD were evaluated by dual x-ray absorptiometry scans and wrist x-rays to estimate bone density and bone age, respectively. Z-scores were determined on the basis of chronological age. Each patient was assigned a "corrected" birth date that was calculated according to bone age, and a bone-age-corrected z-score was determined.
RESULTS: Z-scores adjusted for chronological age were lower than those adjusted for bone age. DISCUSSION: We suggest the use of bone age as an alternative to chronological age for analysis of bone mineral density in glucocorticoid-treated patients with DMD. Additional research is required to determine the optimal method to predict fracture risk in this patient group. Muscle Nerve 59:422-425, 2019.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  DXA; Duchenne muscular dystrophy; bone mineral density; glucocorticoid; osteoporosis

Mesh:

Substances:

Year:  2019        PMID: 30636004      PMCID: PMC6417931          DOI: 10.1002/mus.26413

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  15 in total

1.  Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study.

Authors:  Craig M McDonald; Erik K Henricson; Richard T Abresch; Tina Duong; Nanette C Joyce; Fengming Hu; Paula R Clemens; Eric P Hoffman; Avital Cnaan; Heather Gordish-Dressman
Journal:  Lancet       Date:  2017-11-22       Impact factor: 79.321

2.  Prevalence of Duchenne and Becker muscular dystrophies in the United States.

Authors:  Paul A Romitti; Yong Zhu; Soman Puzhankara; Katherine A James; Sarah K Nabukera; Gideon K D Zamba; Emma Ciafaloni; Christopher Cunniff; Charlotte M Druschel; Katherine D Mathews; Dennis J Matthews; F John Meaney; Jennifer G Andrews; Kristin M Caspers Conway; Deborah J Fox; Natalie Street; Melissa M Adams; Julie Bolen
Journal:  Pediatrics       Date:  2015-02-16       Impact factor: 7.124

Review 3.  Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management.

Authors:  David J Birnkrant; Katharine Bushby; Carla M Bann; Susan D Apkon; Angela Blackwell; David Brumbaugh; Laura E Case; Paula R Clemens; Stasia Hadjiyannakis; Shree Pandya; Natalie Street; Jean Tomezsko; Kathryn R Wagner; Leanne M Ward; David R Weber
Journal:  Lancet Neurol       Date:  2018-02-03       Impact factor: 44.182

4.  Bone health in boys with Duchenne Muscular Dystrophy on long-term daily deflazacort therapy.

Authors:  A L Mayo; B C Craven; L C McAdam; W D Biggar
Journal:  Neuromuscul Disord       Date:  2012-07-21       Impact factor: 4.296

5.  Deflazacort treatment of Duchenne muscular dystrophy.

Authors:  W D Biggar; M Gingras; D L Fehlings; V A Harris; C A Steele
Journal:  J Pediatr       Date:  2001-01       Impact factor: 4.406

Review 6.  Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management.

Authors:  David J Birnkrant; Katharine Bushby; Carla M Bann; Benjamin A Alman; Susan D Apkon; Angela Blackwell; Laura E Case; Linda Cripe; Stasia Hadjiyannakis; Aaron K Olson; Daniel W Sheehan; Julie Bolen; David R Weber; Leanne M Ward
Journal:  Lancet Neurol       Date:  2018-02-03       Impact factor: 44.182

7.  The choice of normative pediatric reference database changes spine bone mineral density Z-scores but not the relationship between bone mineral density and prevalent vertebral fractures.

Authors:  Jinhui Ma; Kerry Siminoski; Nathalie Alos; Jacqueline Halton; Josephine Ho; Brian Lentle; MaryAnn Matzinger; Nazih Shenouda; Stephanie Atkinson; Ronald Barr; David A Cabral; Robert Couch; Elizabeth A Cummings; Conrad V Fernandez; Ronald M Grant; Celia Rodd; Anne Marie Sbrocchi; Maya Scharke; Frank Rauch; Leanne M Ward
Journal:  J Clin Endocrinol Metab       Date:  2014-12-11       Impact factor: 5.958

8.  Height measurement of patients with neuromuscular disease and contractures.

Authors:  F Miller; J Koreska
Journal:  Dev Med Child Neurol       Date:  1992-01       Impact factor: 5.449

9.  Glucocorticoid treatment for the prevention of scoliosis in children with Duchenne muscular dystrophy: long-term follow-up.

Authors:  David E Lebel; John A Corston; Laura C McAdam; W Douglas Biggar; Benjamin A Alman
Journal:  J Bone Joint Surg Am       Date:  2013-06-19       Impact factor: 5.284

Review 10.  Diagnosis of osteoporosis in men, premenopausal women, and children.

Authors: 
Journal:  J Clin Densitom       Date:  2004       Impact factor: 2.963

View more
  2 in total

1.  Bone Mineral Density Assessment by Quantitative Computed Tomography in Glucocorticoid-Treated Boys With Duchenne Muscular Dystrophy: A Linear Mixed-Effects Modeling Approach.

Authors:  Chuan Liu; Dan-Dan Yang; Lu Zhang; Xian-Gao Lei; Feng-Lin Jia; Yi Liao; Xi-Jian Chen; Gang Ning; Wen Luo; Hai-Bo Qu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-23       Impact factor: 5.555

2.  The role of delayed bone age in the evaluation of stature and bone health in glucocorticoid treated patients with Duchenne muscular dystrophy.

Authors:  E J Annexstad; J Bollerslev; J Westvik; A G Myhre; K Godang; I Holm; M Rasmussen
Journal:  Int J Pediatr Endocrinol       Date:  2019-12-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.